Swissmedic Grants Approval for IFINWIL® to Combat High-Risk Neuroblastoma in Children Norgine celebrates Swissmedic's approval of IFINWIL® for treating high-risk neuroblastoma in children, enhancing treatment access in Europe.

Swissmedic Grants Approval for IFINWIL® to Combat High-Risk Neuroblastoma in Children #Switzerland #Neuroblastoma #Norgine #IFINWIL® #Uxbirdge